Plasticell and National University of Ireland Form Stem-Cell Pact
The collaboration will focus on methods to eradicate cancer stem cells
Biotech company, Plasticell, announced that it has entered into an agreement with National University of Ireland, Galway (NUI Galway) to collaborate on research targeting cancer stem cells. Cancer stem cells are often resistant to chemotherapy and thought to be the cause of relapse following treatment. However, it has been observed that cancer stem cells can become susceptible to chemotherapy when appropriately stimulated by certain drugs; such an approach can lead to complete remission of the tumor after treatment is withdrawn.
Plasticell will use its proprietary Combinatorial Cell Culture (CombiCult) platform to discover combinations of drugs, growth factors, and chemotherapeutic agents that are capable of eradicating cancer stem cells in leukemia. Research work will be carried out at Plasticell and in Dr. Eva Szegezdi’s laboratory at the Apoptosis Research Centre, NUI Galway. This collaboration is part funded by an Enterprise Partnership grant from the Irish Research Council.
Source: Plasticell
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
